The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

rss · The Hill 2026-11-19T17:30:00Z en
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.

This article is available on the publisher's site.

Read on The Hill
Highlight